| Targeting miR-155 to treat experimental scleroderma Q Yan, J Chen, W Li, C Bao, Q Fu Scientific reports 6 (1), 20314, 2016 | 70 | 2016 |
| Aberrant activation of the WNT/β-catenin signaling pathway in lupus nephritis X Wang, X Huang, Q Yan, C Bao PLoS One 9 (1), e84852, 2014 | 58 | 2014 |
| Iguratimod represses B cell terminal differentiation linked with the inhibition of PKC/EGR1 axis Y Ye, M Liu, L Tang, F Du, Y Liu, P Hao, Q Fu, Q Guo, Q Yan, X Zhang, ... Arthritis Research & Therapy 21, 1-14, 2019 | 45 | 2019 |
| Prevention of immune nephritis by the small molecular weight immunomodulator iguratimod in MRL/lpr mice Q Yan, F Du, X Huang, Q Fu, S Chen, D Dai, C Bao PLoS One 9 (10), e108273, 2014 | 37 | 2014 |
| Early detection of silent myocardial impairment in drug‐naive patients with new‐onset systemic lupus erythematosus: a three‐center prospective study Q Guo, LM Wu, Z Wang, JY Shen, X Su, CQ Wang, XR Gong, QR Yan, ... Arthritis & Rheumatology 70 (12), 2014-2024, 2018 | 35 | 2018 |
| High incidence and mortality of Pneumocystis jirovecii infection in anti-MDA5-antibody-positive dermatomyositis: experience from a single center L Huang, Q Fu, Y Ye, Y Lin, Q Yan, S Chen Arthritis Research & Therapy 23, 1-8, 2021 | 28 | 2021 |
| Iguratimod as an alternative induction therapy for refractory lupus nephritis: a preliminary investigational study Y Kang, Q Yan, Q Fu, R Wang, M Dai, F Du, Q Dai, P Ye, C Wu, L Lu, ... Arthritis Research & Therapy 22, 1-8, 2020 | 19 | 2020 |
| Serum IL8 and mRNA level of CD11b in circulating neutrophils are increased in clinically amyopathic dermatomyositis with active interstitial lung disease J Zou, J Chen, Q Yan, Q Guo, C Bao Clinical rheumatology 35, 117-125, 2016 | 19 | 2016 |
| Elevated partial antiphospholipid score is a strong risk factor for thrombosis in patients with systemic lupus erythematosus: a validation study J Chen, S Sun, Q Yan, C Bao, Q Fu Clinical rheumatology 35, 333-340, 2016 | 16 | 2016 |
| Association of cytomegalovirus infection with anti-MDA5 antibody-positive dermatomyositis: a prospective cohort study L Huang, W Zhu, Y Ye, X Wu, Q Yan, Z Wang, Y Lin, S Chen Frontiers in Medicine 8, 740154, 2021 | 10 | 2021 |
| Dihydroartemisinin alleviates skin fibrosis and endothelial dysfunction in bleomycin-induced skin fibrosis models R Li, H Yin, J Wang, D He, Q Yan, L Lu Clinical Rheumatology 40 (10), 4269-4277, 2021 | 9 | 2021 |
| Oral IRAK4 inhibitor BAY-1834845 prevents acute respiratory distress syndrome Q Li, R Li, H Yin, S Wang, B Liu, J Li, M Zhou, Q Yan, L Lu Biomedicine & Pharmacotherapy 153, 113459, 2022 | 8 | 2022 |
| Comparison of iguratimod and conventional cyclophosphamide with sequential azathioprine as treatment of active lupus nephritis: study protocol for a multi-center, randomized … Q Yan, F Du, Y Kang, P Ye, X Wang, J Xu, J Tang, N Wang, G Jiang, Z Li, ... Trials 22 (1), 530, 2021 | 8 | 2021 |
| Understanding fibrosis in systemic sclerosis: Novel and emerging treatment approaches H Yin, R Li, L Lu, Q Yan Current Rheumatology Reports 22, 1-15, 2020 | 3 | 2020 |
| THU0355 IGURATIMOD MIGHT TREAT SCLERODERMA WITH INTERRUPTED EGR1/TGF-? LOOP Q Yan, L Shen, D Morales-Cano, X Chen Annals of the Rheumatic Diseases 78 (Suppl 2), 459-459, 2019 | 3 | 2019 |
| Endothelial response to type I interferon contributes to vasculopathy and fibrosis and predicts disease progression of systemic sclerosis H Yin, O Distler, L Shen, X Xu, Y Yuan, R Li, B Liu, Q Li, Q Huang, F Xie, ... Arthritis & Rheumatology 76 (1), 78-91, 2024 | 2 | 2024 |
| Iguratimod attenuated fibrosis in systemic sclerosis via targeting early growth response 1 expression L Shen, H Yin, L Sun, Z Zhang, Y Jin, S Cao, Q Fu, C Fan, C Bao, L Lu, ... Arthritis Research & Therapy 25 (1), 151, 2023 | 2 | 2023 |
| Botulinum toxin for Raynaud's phenomenon associated with systemic sclerosis: comment on the article by Senet et al H Yin, B Liu, Q Li, Q Yan, L Lu Arthritis & Rheumatology 75 (3), 486-486, 2023 | 2 | 2023 |
| Duration biased distribution of clinical and immunological phenotypes in active SLE Q Yan, B Liu, M Yang, Q Li, J Wang, T Li, L Lu Frontiers in Immunology 13, 1044184, 2022 | 2 | 2022 |
| fri0216 iguratimod might be an alternative option for refractory lupus nephritis: a preliminary observational study Q Yan, Y Kang, R Wang, C Bao Annals of the Rheumatic Diseases 78 (Suppl 2), 787-788, 2019 | 2 | 2019 |
